Choline Salicylate and Magnesium Salicylate |
CMT; Tricosal; Trilisate |
Clinical Trial: Magnesium Sulfate For Brain Injury
This study is currently recruiting patients.
|
Purpose
The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the survivors' mental and psychological functioning, including the ability to return to daily life, live independently, and return to work or school.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Brain Injuries Head Injury Brain Concussion | Drug: magnesium sulfate | Phase III |
MedlinePlus related topics: Head and Brain Injuries
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: Magnesium Sulfate for Neuroprotection after Brain Trauma
Study start: August 1999
The purpose of the study is to determine if treating head-injured patients with magnesium sulfate will improve medical, mental, and psychological recovery. In particular, the study will assess each patient's ability to return to daily life, live independently, and return to work or school as done before the head injury occurred. The study will also assess magnesium sulfate's ability to reduce the risk of developing seizures (epilepsy) as well as to improve survival rates after a traumatic brain injury. Patients on the study are assigned randomly (by chance) to either the magnesium sulfate group or the group which gets a placebo. This means they have an equal chance of being in either group. Before the first dose is given, two teaspoons worth of blood are drawn from a vein in the arm. The first dose of magnesium sulfate is 1meq/kg given intravenously within 8 hours of injury. Then a five day continuous intravenous infusion of magnesium sulfate 0.24meq/kg per hour is begun. Daily magnesium levels are checked and the dose changed in order to keep the Magnesium blood level at approximately 4meq/L. If the person does not receive magnesium sulfate, he receives a placebo which looks just like magnesium sulfate but contains no active medication. If the person leaves the hospital before the five days are over, the magnesium or placebo is stopped. Patients on the study will receive a brief exam in person or over the phone at one and three months after the injury to determine whether they have had any seizures and to evaluate how they are functioning and recovering from their head injury. Each evaluation will last about one hour. At six months after the injury, they will have full neuropsychological and psychosocial evaluations done at Harborview. These tests will take about five hours to complete and include tests of vocabulary, problem solving, and coordination. There will be questions about how the injury has affected the way they feel and interact socially. For example, there will be questions about their ability to work, manage personal affairs, what their moods are like, and how anger is handled.
Eligibility
Ages Eligible for Study: 14 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Traumatic brain injury with post-resuscitation Glasgow Coma Scale of 3-12 or, if intubated, motor score of 1-5, or who require emergent neurosurgical intervention precluding the accurate assessment of Glasgow Coma Scale.
Exclusion Criteria:
- Injury greater than 8 hours old
- Age under 14 years
- Compromised renal function (creatinine of 2.0 mb/dl or greater)
- Membership in a vulnerable population (e.g. pregnant woman, prisoner, etc.)
- Residence making follow-up unlikely (e.g. lives outside U.S.)
- Refusal to participate
Location and Contact Information
Washington
University of Washington, Seattle, Washington, 98104, United States; Recruiting
Nancy Temkin, Ph.D., Principal Investigator, University of Washington
More Information
Record last reviewed: December 2004
Last Updated: December 7, 2004
Record first received: February 25, 2000
ClinicalTrials.gov Identifier: NCT00004730
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Choline Salicylate and Magnesium Salicylate (Drug Digest)
- CMT (Drug Digest)

Not Signed In -

